SAB Biotherapeutics annual depreciation and amortization
2020
2021
2022
2023
2024
2025
SAB Biotherapeutics Depreciation & Amortization Growth & History (SABS)
SAB Biotherapeutics's depreciation and amortization was $3.0M for fiscal 2025.
View full SAB Biotherapeutics company overviewSAB Biotherapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $3.0M | −$1.7M | −36.36% |
| 2024 | 2024-12-31 | $4.7M | $1.1M | +28.81% |
| 2023 | 2023-12-31 | $3.7M | $483,722 | +15.26% |
| 2022 | 2022-12-31 | $3.2M | $1.7M | +112.91% |
| 2021 | 2021-12-31 | $1.5M | $1.1M | +288.53% |
| 2020 | 2020-12-31 | $383,142 | — | — |
SAB Biotherapeutics quarterly depreciation and amortization
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $800,000 | $0 | 0.00% |
| Q1 2026 | 2026-03-31 | $730,965 | −$25,630 | −3.39% |
| Q4 2025 | 2025-12-31 | $763,299 | — | — |
| Q3 2025 | 2025-09-30 | $700,000 | −$200,000 | −22.22% |
| Q2 2025 | 2025-06-30 | $800,000 | −$200,000 | −20.00% |
| Q1 2025 | 2025-03-31 | $756,595 | −$1.2M | −61.46% |
| Q3 2024 | 2024-09-30 | $900,000 | −$100,000 | −10.00% |
| Q2 2024 | 2024-06-30 | $1.0M | $100,000 | +11.11% |
| Q1 2024 | 2024-03-31 | $2.0M | $1.1M | +118.49% |
| Q3 2023 | 2023-09-30 | $1.0M | $110,000 | +12.36% |
| Q2 2023 | 2023-06-30 | $900,000 | $150,000 | +20.00% |
| Q1 2023 | 2023-03-31 | $898,453 | $262,218 | +41.21% |
| Q3 2022 | 2022-09-30 | $890,000 | $520,634 | +140.95% |
| Q2 2022 | 2022-06-30 | $750,000 | $491,109 | +189.70% |
| Q1 2022 | 2022-03-31 | $636,235 | $400,276 | +169.64% |
| Q3 2021 | 2021-09-30 | $369,366 | — | — |
| Q2 2021 | 2021-06-30 | $258,891 | — | — |
| Q1 2021 | 2021-03-31 | $235,959 | — | — |
SAB Biotherapeutics depreciation and amortization trends
Over the last five fiscal years, SAB Biotherapeutics's depreciation and amortization increased from $383,142 to $3.0M, a change of $2.6M. The latest reported quarter, Q2 2026, shows $800,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review SAB Biotherapeutics source filings ↗